Health Catalyst stock target cut to $7 at RBC Capital

The analyst at RBC Capital expressed optimism about Health Catalyst (NASDAQ:HCAT)'s bookings outlook for 2025, which anticipates around 40 net new clients compared to 21 in 2024. However, the firm is awaiting the translation of these bookings into actual revenue before considering a more positive adjustment to their rating.

The lowered price target reflects the cautious stance of RBC Capital as they monitor Health Catalyst's performance and its ability to convert new client bookings into sustained revenue growth. The current Sector Perform rating indicates that RBC Capital advises investors to maintain their positions in Health Catalyst stock until more definitive signs of revenue growth are evident.

For deeper insights into Health Catalyst's financial health, valuation metrics, and growth potential, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence. For deeper insights into Health Catalyst's financial health, valuation metrics, and growth potential, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.

The analyst at RBC Capital expressed optimism about Health Catalyst's bookings outlook for 2025, which anticipates around 40 net new clients compared to 21 in 2024. However, the firm is awaiting the translation of these bookings into actual revenue before considering a more positive adjustment to their rating.

The lowered price target reflects the cautious stance of RBC Capital as they monitor Health Catalyst's performance and its ability to convert new client bookings into sustained revenue growth. The current Sector Perform rating indicates that RBC Capital advises investors to maintain their positions in Health Catalyst stock until more definitive signs of revenue growth are evident.

For deeper insights into Health Catalyst's financial health, valuation metrics, and growth potential, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.

The analyst at RBC Capital expressed optimism about Health Catalyst's bookings outlook for 2025, which anticipates around 40 net new clients compared to 21 in 2024. However, the firm is awaiting the translation of these bookings into actual revenue before considering a more positive adjustment to their rating.

The lowered price target reflects the cautious stance of RBC Capital as they monitor Health Catalyst's performance and its ability to convert new client bookings into sustained revenue growth. The current Sector Perform rating indicates that RBC Capital advises investors to maintain their positions in Health Catalyst stock until more definitive signs of revenue growth are evident.

In other recent news, Health Catalyst, a leader in healthcare data and analytics, has made several significant strides. The company recently announced its definitive agreement to acquire Upfront Healthcare Services (NASDAQ:HCSG), a patient engagement platform provider. The transaction, which is expected to be finalized in the first quarter of 2025, aims to enhance Health Catalyst's existing patient engagement portfolio and improve patient access, streamline scheduling, and facilitate better care transitions.

Moreover, Health Catalyst disclosed its third-quarter financial results for 2024, showcasing a positive profit and loss execution and a revenue mix shifting back towards software. Analyst firms such as KeyBanc Capital Markets, Piper Sandler, and Stephens have shown optimism for the company's performance, upgrading the stock and raising the price target. KeyBanc upgraded Health Catalyst from Sector Weight to Overweight, while Piper Sandler and Stephens increased the price target on the company's stock.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.